Xocova (Ensitrelvir) Coming Soon to USA!
A second-generation SARS-CoV-2 antiviral called Xocova could turn out to be a big deal.
Will it cure Long COVID? No. But might it be a genuine tool for people living with it? Possibly.
Something to blunt a bad outcome. Something that buys space to recover through other means. Something that lets a Long COVID patient visit family, see friends, exist in the world with a little less dread.
Something you could take before walking into a medical appointment with a provider who won’t wear an N95.
I have to assume it’s also an option for people whose immune systems are already compromised, by cancer, by treatment, by Long COVID itself.
Will I stop masking in public? No. But would I go out more? Yes. For our family, that alone would be life-changing, the simple knowledge that if we get sick, better options are there.
Will it prevent Long COVID if taken early? I don’t know. Paxlovid doesn’t appear to help with that, but the data on Xocova isn’t in yet. It’s currently approved only for acute infection, but I find myself hoping, genuinely hoping, that preventive use becomes possible someday.
One more thing: it has far fewer drug interactions than Paxlovid. For people already managing complicated medication regimens, that’s not a small thing.
Shionogi expects Xocova (Ensitrelvir) to be in U.S. by mid July based on their supply chain.
Industry analysts anticipate that out of pocket retail cost to be $400-500. No official commercial list price.
Big q is how long for insurance companies add this to their formulary.